chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pfizer booster December 2021. Covid Positive one month later. Had symptoms for 24 days including loss of smell and taste, fatigue, brain fog, congestion, and sore throat. Had lingering fatigue and brain fog for 14 days once other symptoms resolved.
Later that night I started having a headache a low-grade fever sore arm. It only lasted for 24 hours all but the sore arm it lasted for 3 or 4 days.
I was diagnosed with COVID-19 after having had two doses of the Moderna vaccine; lack of efficacy; . This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (I was diagnosed with COVID-19 after having had two doses of the Moderna vaccine) and DRUG INEFFECTIVE (lack of efficacy) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 225421A and 010M20A) for COVID-19 vaccination.     Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID), ZOLPIDEM, SIMVASTATIN and OCRELIZUMAB (OCREVUS) for an unknown indication.   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (I was diagnosed with COVID-19 after having had two doses of the Moderna vaccine) and DRUG INEFFECTIVE (lack of efficacy). At the time of the report, COVID-19 (I was diagnosed with COVID-19 after having had two doses of the Moderna vaccine) had resolved and DRUG INEFFECTIVE (lack of efficacy) outcome was unknown.            No treatment medication were reported.
possible seizure around 45 min after vaccinations, patient was located in major electronics department with a lot of TVs and lights, caregiver pushing her in wheelchair, her eyes were closed. Paramedics were called to check patient out.
pt stated they had swelling of the neck/ears and a cough. told them if any swelling of mouth or trouble breathing to go to doctor.
pt recv vax 20MAR96 & cried for 2 days & dec eating, low grade temp;reporter felt not criteria for on going crying
Pt called pharmacy at approximately 6:30pm 10/3/18 and reported that after going for a run (time not stated) he felt tightness in his chest and had some trouble breathing (not normal for patient). Pt called again at approximately 6:45pm 10/3/18 and stated that he felt like the chest-tightness had worsened and that his throat felt like it was closing. Pt was advised to seek treatment at an urgent care or emergency room--pt declined. RPh spoke with pt at approximately 7:45pm to follow-up with pt's condition. Pt stated he took "2 allergy pills" and was feeling better. He no longer felt as though his throat was closing and the chest tightness had started to lessen.
Extreme nausea and stomach cramping. Arm soreness. Nausea came on very quickly once it began, 18 hours following vaccine. Took OTC anti nausea to relieve the worst of the nausea, stomach cramping was immobilizing for 5 hours. Loss of appepite for 24 hours. Cramping subsided fairly quickly once it began improving.
Received a dose of a vial after 12 hours of initial puncture; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received a dose of a vial after 12 hours of initial puncture) in a 57-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Jul-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Jul-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received a dose of a vial after 12 hours of initial puncture). On 09-Jul-2021, EXPIRED PRODUCT ADMINISTERED (Received a dose of a vial after 12 hours of initial puncture) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   It was reported that the vial was punctured on 01 Jun 2021. Vial was stored in refrigerator once punctured, in freezer prior to puncture.  No concomitant medication was reported. No treatment information was provided.
Post vax, the pt developed erythema at injection site and hives on left lateral thigh and left and right inner thighs.
Information has been received from a physician concerning a 4 month old female patient who was vaccinated at another physician's office with ROTATEQ during her 2nd month wellness check up.  Concomitant vaccinations on the same day were unspecified.  It was noted that the patient stopped breathing after leaving the physician's office.  The patient was rushed to the emergency room.  It was unspecified if lab studies were performed.  The patient was not hospitalized.  At the time of the report, the patient's status was unknown.  There was no product quality complaint involved.  Upon internal review "stopped breathing" was considered an other important medical event.  Additional information has been requested.
adverse event/side effects; This spontaneous report was received from a female patient of unknown age referring to herself. Her pertinent medical history, concomitant medications and drug reactions or allergies were unknown.  On an unknown date (reported as when being "much younger"), the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (formulation, strength, dose, anatomical location, route of administration, lot # and expiration date were not reported) as prophylaxis. The patient reported having experienced adverse event/side effects on an unknown date but could not recall the side effects. The patient reported that her parents did not know how to report the side effects to the company. The outcome of the event was unknown.  The relatedness between the suspect therapy and the event was not provided.
On 9/7, developed painful, vesicular rash over R posterior neck. On 10/7, developed similar rash over B sacral spine and on 11/8, over R groin. On 10/19, she received PREVNAR-13, which she had previously received in 2015, and FLUZONE HIGH-DOSE. In 2012, she experienced a single vesicle after receiving the ZOSTAVAX vaccine.
Extreme dizziness and vertigo , 1 week after 2nd dose. Urgent care and ER trip, still had extremem vertigo present on 11/16
Headache; This is a spontaneous report from a contactable consumer (patient). A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, lot number: SC3184, expiry date: unknown) via unspecified route of administration, on an unspecified date as dose 1, single for covid-19 immunisation. Patients medical history and concomitant medications were not reported. It seemed like patient got headache since got the (first dose) shot. Patient got it on Sunday and had headache in morning Monday and still had it today (unspecified date). Patient wanted to know what should be done to get rid of the headache. The outcome of event was unknown.
Information has been received from a medical assistant referring to a patient of unknown age and gender. Information about concurrent condition, concomitant medication, drug reactions/allergies and medical history was not provided. On 13-SEP-2018, the patient was administered an improperly stored dose of RECOMBIVAX HB (1 dosage form (DF), lot# R004185, expiration date 06-NOV-2020; strength, frequency and route were not reported), and ROTATEQ (lot# R002516, expiration date 13-SEP-2019; strength, frequency and route were not reported) for prophylaxis. It was also reported that on that day, VAQTA (1DF; strength, frequency, lot#, expiration date and route were not reported), and GARDASIL 9 (1DF; strength, frequency, lot#, expiration date and route were not reported) were also administered for prophylaxis. The vaccines were exposed to the temperature excursion of 32 Fahrenheit (F) degree to 35 F degree (34 F degree) for 1 hour and 47 minutes. No adverse event was reported. The vaccine was noted OK for use. It was a temperature excursion fridge temperature was noted at 34 degrees. There was no previous temperature excursion. No data logger was involved.
This case was reported by a consumer and described the occurrence of fever in a female patient who received SHINGRIX for prophylaxis. In December 2018, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced fever, nausea, fatigue and injection site pain. On an unknown date, the outcome of the fever, nausea, fatigue and injection site pain were recovered/resolved. It was unknown if the reporter considered the fever, nausea, fatigue and injection site pain to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient experienced fever, nausea, fatigue and injection site pain post vaccination. All the symptoms listed, required the patient to take 2 days of sick leave from work. The patient full recovery after 3 to 4 days with no prolonged symptoms. This is 1 of the 6 cases, reported by the same reporter.
R deltoid injection site, sore, tender radiation to neck, warm to the touch, redness. S/B ER MD prescription for steroids/prednisone.
chills; muscle ache; low grade fever up to 100.3; a red flushed rash on neck and chest; This is a spontaneous report from a contactable nurse (patient). A 39-year-old non-pregnant female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EK9231), via an unspecified route of administration on 09Jan2021 12:00 at single dose in left arm for covid-19 immunization. The patient had no other medical history and no known allergies. Concomitant medication included vitamin D3 and daily multivitamin. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL0140), on 20Dec2020 07:30 in left arm for covid-19 immunization. The patient had no covid prior vaccination and no covid tested post vaccination. The patient reported that on 10Jan2021 02:00 about 14 hours after 2nd vaccine she had chills, muscle aches, and low grade fever up to 100.3 for the next 12 hours. Then she experienced a red flushed rash on neck and chest for about 12 hours after the previous symptoms. All symptoms gone after about 24 hours. The patient did not receive any treatments for events. The outcome of the events was recovered on 11Jan2021.
patient fainted/seized after receiving her flu and covid19 vaccines. She appeared confused but admitted that her entire family has a history of vasovagal responses. BP at 2:44pm was 125/80 , patient was given water able to sit upright in our waiting area.  A vaccine was administered to a child who then screamed, which caused the patient to pass out yet again in our waiting area.  Staff was then called to the waiting area, lay patient down with feet lifted on the chair, applied a cool compress.  Patient's color eventually returned and her blood pressure was 104/77 at 3:06pm.  911 was refused.  Mom arrived and stated that patient has a follow up appt with her primary md.
Hot , swollen lump on arm at vaccination site that started out the size of a quarter. Has since grown to the size of my palm. Very sore to the touch. Very swollen.
Injection site started hurting 3 hours after shot.  Fever, chills, body aches & fatigue followed 11 hours later.  Fever subsided after 3 hours; chills after 6 hours.  Body aches, headache & fatigue continued for 3 days & everything went back to normal.  Had to call out of work for 3 days.
0830- Pt received immunization. 0835- Pt complains of dizziness and nausea. Pt is pale, diaphoretic, and sleepy. 0848- BP 90/40, HR 68, RR 20. No c/o SOB or difficulty breathing. 0855 - Pt. skin color normal. No diaphoresis, & states "I'm feeling better" & is smiling. 0857 - Pt. ambulating. Given instructions to call PCP for any further problems or concerns.
Vaccine admin on 9/29/07. Pharmacist followed-up on 9/31/07 and patient reported redness around the site of injection site on 10/3/07. Patient came by the pharmacist w/ raised blisters at the site on injection.
Patient was administered the primary COVID19 Pfizer -BioNTech vaccine when indicated vaccine should have been COVID19 Pfizer-BioNTech Bivalent. The patient has not reported any adverse effects, only received incorrect Pfizer vaccine.
pain on rt arm (where tetanus shot was given) radiating to the neck & face swelling rt side of face;pt recv vax 17APR97 & rt arm still hurts & feels numb;sx do not improve w/med;
Tendonitis; This spontaneous case was reported by a consumer and describes the occurrence of TENDONITIS (Tendonitis) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Multiple sclerosis (Relapsing remitting).    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose. On an unknown date, the patient experienced TENDONITIS (Tendonitis). At the time of the report, TENDONITIS (Tendonitis) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided.
The adverse event was Shingles. I got prescription medication called Valacyclovir HCL , which included an increase in my Gabapentin. I'm still suffering from the shingles.  It's not the external sores that was the original manifestation. It's the subcutaneous, an infection of my nerves. My nerves itch. I have to take an Aleve in the morning and night, and then I take the maximum dosage of Gabapentin.
Patient states her right arm/shoulder has been bothering her since the vaccine was given. She went to her Dr who diagnosed her with bursitis and prescribed an anti-inflammatory. Dr will follow up with pt.
Mother noticed left thigh swollen, pink this morning. Vaccine given 2 days prior, technician felt most likely DTap. Pt walking ok, no fever. TX Benadryl, Keflex. Warmth pt says hurts.
Chief complaint: dizziness Vitals 126/84, RR 16, HR 92, spO2 99%
Case number PHEH2015US020111, is an initial spontaneous report received from a pharmacist on 07 Oct 2015. This report refers to a 22 year old female patient. Medical history and concomitant medication was not reported. She received AFLURIA (other manufacturer, batch number: unknown) on 10 Sep 2015 and influenza vaccine INN (manufacturer and batch number unknown) on 07 Oct 2015. The patient received 2 doses of flu vaccines within 4 weeks apart from one another. No adverse event was reported. No further information was provided.
Failed to work.  I became fully infected with Covid 19 months after receiving the booster shot.
I have an MRI and it was an allegiant and infiltrate. so, then it was biopsy and shown to have inflammation. An there is some report that it has shown that this could be a side effect of the vaccine. I told by the doctor to make a report of this symptoms.
PATIENT DEVELOPED VERY BIG BRUCE  AT THE INJECTIONS SITE AFTER PFIZER BOOSTER DOSE. EVEN AFTER 12 DAYS OF SHOT, IT'S STILL VERY ITCHY. PATIENT DID NOT HAD THIS KIND OF REACTION FROM FIRST TWO DOSES.  PATIENT IS AWAITNG FROM DOCTOR'S RESPONSE ON BRUSE.
On Jan 18th I experienced swelling of my upper lip.  In 1980 I had silicone filler injected ONLY into my upper lip. It remains swollen today (Jan 19th). I have not taken any medication thus far to address this inflammation.
Around 28 hours after vaccine appointment, I noticed an oval rash near, but not directly on, the injection site, as well as muscular pain under the rash. Painful to the touch but not itchy or bothersome otherwise.
not feeling well (booster)/feels like when had Covid-19; shaky (booster); 4 fingers were blue, white in the tips and numb (booster); 4 fingers were blue, white in the tips and numb (booster); chills (booster); This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (not feeling well (booster)/feels like when had Covid-19), TREMOR (shaky (booster)), SKIN DISCOLOURATION (4 fingers were blue, white in the tips and numb (booster)), HYPOAESTHESIA (4 fingers were blue, white in the tips and numb (booster)) and CHILLS (chills (booster)) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 067H21A, 031B21A and 002B21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19.   On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 14-Jan-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In January 2022, the patient experienced MALAISE (not feeling well (booster)/feels like when had Covid-19), TREMOR (shaky (booster)), SKIN DISCOLOURATION (4 fingers were blue, white in the tips and numb (booster)), HYPOAESTHESIA (4 fingers were blue, white in the tips and numb (booster)) and CHILLS (chills (booster)). The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]) for Adverse event, at a dose of 1 dosage form. At the time of the report, MALAISE (not feeling well (booster)/feels like when had Covid-19), TREMOR (shaky (booster)), SKIN DISCOLOURATION (4 fingers were blue, white in the tips and numb (booster)), HYPOAESTHESIA (4 fingers were blue, white in the tips and numb (booster)) and CHILLS (chills (booster)) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In January 2022, Body temperature: 97.5 (normal) 97.5°F.         After booster dose patient body temperature was 97.5F also felt like when had COVID-19 No concomitant information were reported by the reporter   This case was linked to MOD-2022-451541, MOD-2022-451540 (Patient Link).
CONFIRMED CLINICAL VACCINE FAILURE; CONFIRMED COVID 19 INFECTION; This spontaneous report received from a patient via other manufacturer Pfizer concerned a 42 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included: multiple sclerosis (MS) and drug allergy (unspecified drug). The patient was not pregnant at the time of this report.  The patient received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin, and batch number were not reported) dose was not reported, 1 total, administered on 12-MAR-2021 to Left Arm for covid-19 prophylaxis. Age at time of vaccination 41 years old. The batch number was not reported and has been requested. It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine. The patient received elasomeran (Moderna Covid-19 vaccine) (dose number in series 2) (form of admin, route of admin, batch number and expiry date were not reported) dose was not reported, administered on 09-NOV-2021 to Left Arm for covid-19 prophylaxis.  On an unspecified date in 2022, the patient experienced confirmed covid-19 infection (dose number in series 2). The patient received non-company suspect Paxlovid (Nirmatrelvir; ritonavir) (form of admin, route of admin, batch number and expiry date were not reported) therapy started on 01-JUL-2022. Therapy ended on 06-JUL-2022 administered for covid-19 treatment. Later, 5 days after treatment ended, the patient had Covid rebound and recurrence of symptoms (unspecified), and positive test which led to confirmed vaccination failure (dose series 1). Laboratory data (dates unspecified) included: COVID-19 virus test Positive. The action taken with covid-19 vaccine ad26.cov2.s, and elasomeran was not applicable and Paxlovid was discontinued. The patient recovered from confirmed covid 19 infection on 16-JUL-2022, and the outcome of confirmed clinical vaccine failure was not reported. This report was serious (Other Medically Important Condition). This report was associated with product quality complaint 90000243929.; Sender's Comments: V0: 20220752345 - Covid-19 vaccine ad26.cov2.s -CONFIRMED CLINICAL VACCINATION FAILURE. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event(s) than the drug. Specifically: SPECIAL SITUATIONS. Therefore, this event(s) is considered not related.
I had muscle aches in left arm and hardness around injection area a couple hours after receiving the shot, in addition to muscle aches in my other arm and fingers. Then I started to get a slight fever about 11 hours after receiving the second shot, which was accompanied by chills. I took an over the counter pain reliever which helped ease symptoms. The morning after receiving the shot I was experiencing fatigue, muscle aches (in areas previously described and in my legs), and intermittent chills and slight fever which I continued to take over the counter mediation for. I was dizzy a little bit the next day, but that could have been part of the fatigue. I had a short burst of coughing around noon the next day (after receiving the second dose) which lasted about half an hour.  About 24 hours after receiving second dose the fever and chills stopped after I sweat quite a bit.
Patient started feeling faint after vaccination while sitting. Patient slowly slid out of seat onto the ground. Parents report child having seizure-like jerking activity.
Information has been received from a physician and a licensed practical nurse concerning a 63 year old female with no known allergies, gastrooesophageal reflux disease and rheumatoid arthritis and a history of Bell's palsy 20 years ago and diverticulitis who on 12-MAR-2008 was vaccinated with 0.65mL of zoster vaccine live (Oka/Merck). Concomitant therapy included methotrexate, LOTREL and PLAQUENIL. Subsequently, after vaccination the patient presented with numbness in her face and the right side of her nose (in the area where she was affected by Bell's palsy), and intermittent tingling on her lips and nose. Unspecified medical attention was sought. There were no lab studies performed. On an unspecified date the patient recovered. There was no product quality complaint involved. Additional information has been requested.
Patient had her Johnson and Johnson Covid 19 vaccine on Friday April 9, 2021. Prior to the vaccine patient displayed no noticeable signs of deteriorating health. Over the next two days, friends of the patient attempted to contact her with no success. Finally after several hours of no contact, the grandchildren of the patients friend went to her apartment and found the patient lying on the couch unresponsive. When the patient was found, her leg was swollen. She was cold and not breathing. She passed away after receiving the Johnson and Johnson vaccine.